A receptor thought to be a cell growth inhibitor actually sends pro-survival signals in small cell lung cancer and is a candidate biomarker for poor prognosis.

Megan Palmer, RN, a nurse in the Palliative Care Unit at Vanderbilt University Medical Center, wears many hats, but she never imagined writing a song about a perfect Stetson cowboy hat would hold such powerful meaning in her life.

Sarah Rohde long had an interest in treating cancer, and her research during her undergraduate and medical school years at the University of Virginia underscored that. What she didn’t expect was to become a surgeon.

Patient ambassador Lily Hensiek, center, served as Mayor of Smashville at the Nashville Predators Hockey Fights Cancer Night on Saturday, Nov. 3.

Vanderbilt researchers are developing new approaches to study the mechanisms underlying why breast cancer cells home to bone and lie dormant, evading treatment.

Vanderbilt researchers have characterized the functional transfer of long RNAs between colorectal cancer cells — a form of cell-cell communication that may contribute to cancer aggressiveness.

Patients with stage IV small-cell lung cancer lived longer when given the immunotherapy atezolizumab with chemotherapy, setting the stage for what could become the first new treatment approved in decades for this particularly aggressive form of lung cancer.